Termination by Roche. In the event that Roche has exercised its First Option or its Second Option for a Compound, as applicable, and ROCHE decides to stop development or commercialisation of Compound (s) or Products for any reason, ROCHE may terminate this Agreement in its entirety or on a country-by country or Product-by Product basis at any time with six (6) months prior written notice, provided that ROCHE has offered the rights and licenses under this Agreement back to ENS by written notice and ENS has declined to accept such offer by written notice within ninety (90) days. In the event that ENS accepts the offer, the terms of this Agreement apply and regarding the transfer of data Sections 13.1.3., 13.1.4. and 13.1. 5. shall apply mutatis mutandis.
Termination by Roche without Cause After the Effective Date After the Effective Date, Roche shall have the right to terminate this Agreement at any time as a whole or on a Product-by-Product or country-by-country basis upon ninety (90) days prior written notice before First Commercial Sale in the Territory or upon one hundred eighty (180) days prior written notice after the First Commercial Sale in the Territory. The effective date of termination under this Section 18.2.2 shall be the date ninety (90) days (or one hundred eighty (180) days as the case may be) after Roche provides such written notice to Eleven.
Termination by Roche for Breach by Pieris or Pieris’ Insolvency Upon any termination by Roche for breach by Pieris or Pieris’ Insolvency, Roche and its Affiliates may upon notice retain all rights and licenses granted to Roche by Pieris under this Agreement; provided that after the effective date of termination the amounts of such payments and royalties that otherwise would have become due and payable shall continue to be due and payable to Pieris or its successor in interest (as applicable).
Termination by Roche. Roche shall have the right to terminate this Agreement as a whole, or on a Product-by- Product and/or country-by-country basis, for any reason or for no reason at any time, upon ninety (90) days’ prior written notice to Emisphere. If Roche terminates this Agreement with respect to a particular Product or country, then the licenses granted to Roche under Sections 5.1(a)(i) and 5.1(a)(ii), if then in effect, shall automatically
Termination by Roche without cause after the Research Term If Roche terminates this Agreement after the Research Term for no cause in application of Section 15.2.4, then:
a) all licenses granted to Roche by Partner in the country for which the Agreement is terminated shall terminate on the effective date of termination; and
b) Partner shall retain a royalty free, non-exclusive sublicensable, fully-paid up perpetual license to use the Baseline Data to develop, have developed, make, have made, import, export, sell and have sold Diagnostic Products other than Companion Diagnostics in the Territory.
Termination by Roche without a Cause Roche shall have the right to terminate this Agreement at any time *** (i) with *** months prior written notice, if before First Commercial Sale of the first Product for a given Program or (ii) with *** months prior written notice, if after the First Commercial Sale of the first Product for a given Program. The effective date of termination under this Section 18.3.3 shall be the date *** months (or *** months as the case may be) after Roche provides such written notice to Hookipa.
Termination by Roche. After the expiry of the [...***...], Roche shall have the right to terminate this Agreement in its entirety with [...***...] ([...***...]) days prior written notice to SGX.
Termination by Roche. (a) At the end of a two-(2)-year-period from the beginning of the Research Program Roche shall have the option to terminate the Research Program by giving six (6) months prior written notice to Helicon. In addition, if the milestones set forth in Section 6.8.4 have not been achieved by Helicon for reasons not attributable to Roche, then Roche shall have the right to terminate the Agreement by giving ninety (90) days prior written notice.
(b) Upon receipt of such notice, Helicon may, at its sole option, terminate all work under the Research Plan unless otherwise agreed with Roche. If Roche terminates this Agreement pursuant to this Section, it will make the Funding Payments which would otherwise have been due for such notice period. No funding payments shall be executed, if the milestones set forth in Section 6.8.4 have not been achieved for reasons not attributable to Roche.
(c) At the end of the Research Program Roche shall have the right to terminate this Agreement either in whole or with respect to single Targets (Initial Identified Target and/or any Additional Target) licensed by Roche under Section 5.1 at any time, provided, however, that such termination shall not affect any and all rights and royalty obligations by Roche hereunder.
Termination by Roche. Roche may terminate this Agreement for any or no reason upon ninety (90) days prior written notice to Prothena.
Termination by Roche. Roche shall have the right to terminate this Agreement in its entirety or on a Licensed Product-by-Licensed Product or country-by-country basis [***].
